Fig. 2: Median overall survival for patients with unresectable stage III NSCLC who responded to prior chemoradiotherapy, receiving durvalumab or placebo in the PACIFIC clinical trial. | British Journal of Cancer

Fig. 2: Median overall survival for patients with unresectable stage III NSCLC who responded to prior chemoradiotherapy, receiving durvalumab or placebo in the PACIFIC clinical trial.

From: Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Fig. 2

Shown are Kaplan–Meier curves for median OS, defined according to the RECIST v1.1, and assessed by blinded-independent central review. Tick marks indicate censored observations, and vertical dotted lines indicate the times of landmark OS analyses. The intention-to-treat population included all patients who underwent randomisation. Data cut-off for median OS was March 22, 2018, and median follow-up was 25.2 months. Adapted from Antonia et al.34 Reprinted with permission from Massachusetts Medical Society.

Back to article page